M Pavel

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus
    Marianne Pavel
    Department of Hepatology and Gastroenterology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Target Oncol 11:667-675. 2016
  2. ncbi WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine
    Marianne E Pavel
    Medical DepartmentDivision of Hepatology and Gastroenterology including Metabolic Diseases, Campus Virchow Klinikum, Charite University Medicine, Berlin, Germany
    Endocr Relat Cancer 23:T135-T154. 2016
  3. doi Systemic therapeutic options for carcinoid
    Marianne Pavel
    Charite University Medicine, 13353 Berlin, Germany
    Semin Oncol 40:84-99. 2013
  4. doi Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors
    M E Pavel
    Charite Universitatsmedizin Berlin, Department of Gastroenterology and Hepatology, Endocrinology, Diabetes and Metabolic Diseases, Berlin, Germany
    Horm Metab Res 43:844-53. 2011
  5. doi [Metastatic neuroendocrine neoplasms. Non-surgical treatment strategies]
    M Pavel
    Charite Universitatsmedizin Berlin, Augustenburger Platz 1, Berlin, Germany
    Chirurg 82:612-7. 2011
  6. doi Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin
    H Jann
    Department of Hepatology and Gastroenterology, Charite, Berlin, Germany
    Neuroendocrinology 98:137-43. 2013
  7. doi [Poorly differentiated neuroendocrine carcinoma of the larynx. Diagnostic features, treatment strategy, and prognosis]
    M D Jumah
    Klinik für Hals Nasen Ohren Heilkunde, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Chariteplatz 1, 10117, Berlin
    HNO 57:135-41. 2009
  8. doi A matter of the heart: myocardial metastases in neuroendocrine tumors
    H Jann
    Department of Hepatology and Gastroenterology, Charite, Berlin, Germany
    Horm Metab Res 42:967-76. 2010

Collaborators

Detail Information

Publications8

  1. ncbi Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus
    Marianne Pavel
    Department of Hepatology and Gastroenterology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Target Oncol 11:667-675. 2016
    ..An open-label, multi-center, expanded access study was conducted in patients with advanced neuroendocrine tumors (NET) treated with everolimus (10 mg/day) to assess safety and health-related quality of life (HRQOL)...
  2. ncbi WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine
    Marianne E Pavel
    Medical DepartmentDivision of Hepatology and Gastroenterology including Metabolic Diseases, Campus Virchow Klinikum, Charite University Medicine, Berlin, Germany
    Endocr Relat Cancer 23:T135-T154. 2016
    ..However, an improved understanding of the complexity of pathway interactions is required for successful treatment. A systems biology approach is one of the tools that may help to achieve this endeavor...
  3. doi Systemic therapeutic options for carcinoid
    Marianne Pavel
    Charite University Medicine, 13353 Berlin, Germany
    Semin Oncol 40:84-99. 2013
    ..Increased efficacy requires a better understanding of the underlying tumor biology and identification of molecular pathological criteria to allow appropriate preselection of candidates for targeted therapies...
  4. doi Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors
    M E Pavel
    Charite Universitatsmedizin Berlin, Department of Gastroenterology and Hepatology, Endocrinology, Diabetes and Metabolic Diseases, Berlin, Germany
    Horm Metab Res 43:844-53. 2011
    ..This review provides an overview on novel drugs, focus on the impact of recently approved drugs on the management of NET disease, and outline future perspectives...
  5. doi [Metastatic neuroendocrine neoplasms. Non-surgical treatment strategies]
    M Pavel
    Charite Universitatsmedizin Berlin, Augustenburger Platz 1, Berlin, Germany
    Chirurg 82:612-7. 2011
    ..This review presents the management of patients with small intestinal and pancreatic NEN with respect to the functionality and tumor grading. The use of novel targeted drug therapy is included in a therapeutic algorithm...
  6. doi Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin
    H Jann
    Department of Hepatology and Gastroenterology, Charite, Berlin, Germany
    Neuroendocrinology 98:137-43. 2013
    ..The aim of our investigation was to evaluate the antiproliferative effect of SSA in patients with pancreatic NET...
  7. doi [Poorly differentiated neuroendocrine carcinoma of the larynx. Diagnostic features, treatment strategy, and prognosis]
    M D Jumah
    Klinik für Hals Nasen Ohren Heilkunde, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Chariteplatz 1, 10117, Berlin
    HNO 57:135-41. 2009
    ..Small cell carcinoma of the larynx is a rare, poorly differentiated neuroendocrine carcinoma (NEC). It is often diagnosed late, with delayed initiation of adequate therapy...
  8. doi A matter of the heart: myocardial metastases in neuroendocrine tumors
    H Jann
    Department of Hepatology and Gastroenterology, Charite, Berlin, Germany
    Horm Metab Res 42:967-76. 2010
    ..Management of cardiac metastases requires close cooperation between specialists of internal medicine, nuclear medicine, and cardiac surgery...